Key points from article :
The PEARL trial will be the first large-scale human trial with a focus on slowing down aging.
The biohacking community has self experimented with many supplements and drugs over the last few decades.
But little interest from public money sources for funding longevity studies.
Rapamycin is a naturally occurring antifungal antibiotic produced by soil bacteria.
Increases healthspan in many organisms, including yeast, worms, and mice.
PEARL trial will track 200 participants over the course of a year - with four different dosage groups.
It will be a double-blind, randomized, placebo-controlled study and registered with clinicaltrials.gov.
Principal investigator is Dr. James P Watson at UCLA, who was also a PI for the famous TRIIM trial.
A host of biomarkers will be tested once the study begins, 6 months into the study, and at the 12-month mark.
Trial is being crowd-funded by Lifespan.io with a range of rewards including t-shirt, books and even lab coats!
